Molecular Determinants of the Selectivity and Potency of α-conotoxin Vc1.1 for Human Nicotinic Acetylcholine Receptors

Overview

Journal J Biol Chem

Specialty Biochemistry

Date 2024 Nov 28

PMID 39608712

Authors

Han-Shen Tae

Andrew Hung

Richard J Clark

David J Adams

Affiliations

Soon will be listed here.

Abstract

The α-conotoxins (α-Ctxs) are short, disulfide-rich peptides derived from the venom of the Conus marine snails, primarily acting as antagonists of nicotinic acetylcholine receptors (nAChRs). Specifically, α-Ctx Vc1.1, a 16-amino acid peptide from Conus victoriae, competitively antagonizes non-muscle nAChRs, inhibits nicotine-induced currents in bovine chromaffin cells, and alleviates neuropathic pain in rat models. Although Vc1.1 selectively inhibits rat α9α10 nAChRs, its potency and selectivity across human nAChR subtypes remain unresolved. In this study, we assessed the activity of Vc1.1 on human (h) nAChRs heterologously expressed in Xenopus laevis oocytes using the two-electrode voltage clamp technique and simulated interactions using computational modeling. Vc1.1 selectively antagonized homomeric α9 and heteromeric α3β2 nAChRs, with half-maximal inhibitory concentrations (IC) of 160 nM and 232 nM, respectively. At hα9[N179A]α10, Vc1.1 exhibited a 20-fold decrease in potency compared to hα9α10, due to the loss of hydrogen bonding with Vc1.1-D11. Conversely, Vc1.1 was four-fold more potent at hα3β2[E86A] compared to hα3β2, possibly influenced by the proximal residue β2-K104, as suggested by molecular dynamics (MD) simulations. Additionally, Vc1.1's potency doubled at hα9[N213K]α10, whereas it remained unchanged at hα9[N213R]α10 nAChRs. MD simulations indicate that altered interactions between the mutant hα9 N179A, N213K, and N213R side chains and Vc1.1-D5 may partly explain these changes in potency. The inhibitory action of Vc1.1 at α9-containing nAChRs is particularly relevant given their role in neuroinflammation, presenting a potential therapeutic pathway for alleviating neuropathic and inflammatory pain. This study provides valuable insights into the rational design of Vc1.1-derived α-Ctxs with enhanced nAChR subtype selectivity.

References

Yu R, Kompella S, Adams D, Craik D, Kaas Q . Determination of the α-conotoxin Vc1.1 binding site on the α9α10 nicotinic acetylcholine receptor. J Med Chem. 2013; 56(9):3557-67. DOI: 10.1021/jm400041h. View

Dallakyan S, Olson A . Small-molecule library screening by docking with PyRx. Methods Mol Biol. 2015; 1263:243-50. DOI: 10.1007/978-1-4939-2269-7_19. View

Hone A, McIntosh J . Nicotinic acetylcholine receptors: Therapeutic targets for novel ligands to treat pain and inflammation. Pharmacol Res. 2023; 190:106715. PMC: 10691827. DOI: 10.1016/j.phrs.2023.106715. View

Improgo M, Tapper A, Gardner P . Nicotinic acetylcholine receptor-mediated mechanisms in lung cancer. Biochem Pharmacol. 2011; 82(8):1015-21. DOI: 10.1016/j.bcp.2011.05.020. View

MacKerell A, Bashford D, Bellott M, Dunbrack R, Evanseck J, Field M . All-atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem B. 2014; 102(18):3586-616. DOI: 10.1021/jp973084f. View

Wang H, Li X, Zhangsun D, Yu G, Su R, Luo S . The α9α10 Nicotinic Acetylcholine Receptor Antagonist αO-Conotoxin GeXIVA[1,2] Alleviates and Reverses Chemotherapy-Induced Neuropathic Pain. Mar Drugs. 2019; 17(5). PMC: 6562493. DOI: 10.3390/md17050265. View

Halder N, Lal G . Cholinergic System and Its Therapeutic Importance in Inflammation and Autoimmunity. Front Immunol. 2021; 12:660342. PMC: 8082108. DOI: 10.3389/fimmu.2021.660342. View

Kuryatov A, Olale F, Cooper J, Choi C, Lindstrom J . Human alpha6 AChR subtypes: subunit composition, assembly, and pharmacological responses. Neuropharmacology. 2000; 39(13):2570-90. DOI: 10.1016/s0028-3908(00)00144-1. View

Clark R, Craik D . Engineering cyclic peptide toxins. Methods Enzymol. 2012; 503:57-74. DOI: 10.1016/B978-0-12-396962-0.00003-3. View

10.

Takata K, Kimura H, Yanagisawa D, Harada K, Nishimura K, Kitamura Y . Nicotinic Acetylcholine Receptors and Microglia as Therapeutic and Imaging Targets in Alzheimer's Disease. Molecules. 2022; 27(9). PMC: 9102429. DOI: 10.3390/molecules27092780. View

11.

Pacini A, Micheli L, Maresca M, Branca J, McIntosh J, Ghelardini C . The α9α10 nicotinic receptor antagonist α-conotoxin RgIA prevents neuropathic pain induced by oxaliplatin treatment. Exp Neurol. 2016; 282:37-48. DOI: 10.1016/j.expneurol.2016.04.022. View

12.

Sandall D, Satkunanathan N, Keays D, Polidano M, Liping X, Pham V . A novel alpha-conotoxin identified by gene sequencing is active in suppressing the vascular response to selective stimulation of sensory nerves in vivo. Biochemistry. 2003; 42(22):6904-11. DOI: 10.1021/bi034043e. View

13.

Mucchietto V, Crespi A, Fasoli F, Clementi F, Gotti C . Neuronal Acetylcholine Nicotinic Receptors as New Targets for Lung Cancer Treatment. Curr Pharm Des. 2016; 22(14):2160-9. DOI: 10.2174/1381612822666160203144114. View

14.

Tae H, Gao B, Jin A, Alewood P, Adams D . Globular and ribbon isomers of Conus geographus α-conotoxins antagonize human nicotinic acetylcholine receptors. Biochem Pharmacol. 2021; 190:114638. DOI: 10.1016/j.bcp.2021.114638. View

15.

Biaggioni I . The Pharmacology of Autonomic Failure: From Hypotension to Hypertension. Pharmacol Rev. 2016; 69(1):53-62. PMC: 6047298. DOI: 10.1124/pr.115.012161. View

16.

Chu X, Tae H, Xu Q, Jiang T, Adams D, Yu R . α-Conotoxin Vc1.1 Structure-Activity Relationship at the Human α9α10 Nicotinic Acetylcholine Receptor Investigated by Minimal Side Chain Replacement. ACS Chem Neurosci. 2019; 10(10):4328-4336. DOI: 10.1021/acschemneuro.9b00389. View

17.

Nevin S, Clark R, Klimis H, Christie M, Craik D, Adams D . Are alpha9alpha10 nicotinic acetylcholine receptors a pain target for alpha-conotoxins?. Mol Pharmacol. 2007; 72(6):1406-10. DOI: 10.1124/mol.107.040568. View

18.

Yu R, Seymour V, Berecki G, Jia X, Akcan M, Adams D . Less is More: Design of a Highly Stable Disulfide-Deleted Mutant of Analgesic Cyclic α-Conotoxin Vc1.1. Sci Rep. 2015; 5:13264. PMC: 4542547. DOI: 10.1038/srep13264. View

19.

Shelukhina I, Siniavin A, Kasheverov I, Ojomoko L, Tsetlin V, Utkin Y . α7- and α9-Containing Nicotinic Acetylcholine Receptors in the Functioning of Immune System and in Pain. Int J Mol Sci. 2023; 24(7). PMC: 10095066. DOI: 10.3390/ijms24076524. View

20.

McIntosh J, Dowell C, Watkins M, Garrett J, Yoshikami D, Olivera B . Alpha-conotoxin GIC from Conus geographus, a novel peptide antagonist of nicotinic acetylcholine receptors. J Biol Chem. 2002; 277(37):33610-5. DOI: 10.1074/jbc.M205102200. View